Loading stock data…
Lisata Therapeutics (LSTA)
$3.39+0.03 (+0.89%)
Market ClosedLast close Jun 29
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lisata Therapeutics, Inc. in the Healthcare sector is trading at $3.39 with a market capitalization of $31M. Wall Street consensus targets $4.00 (1 analysts), implying a +18.0% move over the next 12 months. The stock is currently 33% below its 52-week high of $5.07, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +18.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $100,000 | $0↓ | $70,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.94M↓ | -$3.08M↑ | -$4.41M↑ | -$4.87M↑ | -$5.85M |
| Net Income | -$4.49M↓ | -$2.95M↑ | -$4.25M↑ | -$4.66M↑ | -$4.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.65%
Volume
Today's trading volume
15,173
Recent News
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones. Kuva's wholly owned subsidiary Kuva Acquisition Corp...
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will...
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
Major stock indexes in the United States recently rebounded, closing sharply higher after a period of volatility driven by geopolitical tensions and economic policy shifts. In this context, investors are increasingly looking for opportunities that balance affordability with growth potential. While the term 'penny stocks' may seem outdated, it still refers to smaller or emerging companies that can offer significant value when backed by strong financials. In this article, we explore three penny...
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook
Why the Lisata Therapeutics Price Target Just Changed Lisata Therapeutics just saw its price target revised, and that shift reflects a fresh read on the company’s current position and risks rather than a simple reaction to short term share moves. With new commentary reshaping how some analysts frame the story, the focus is now less on where the stock has been and more on how its narrative is being reassessed. Stay with this article to see how you can keep on top of future shifts in that...
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...
Lisata Therapeutics Inc (LSTA) reports positive development milestones and strategic partnerships, while navigating funding hurdles for future trials.